Immunose FLU(Eurocine Vaccines AB)(Immunose FLU(Eurocine Vaccines AB))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

流感病毒感染

原研机构

Eurocine Vaccines AB

在研机构-

非在研机构

Eurocine Vaccines AB

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Immunose FLU(Eurocine Vaccines AB) 相关的临床试验

NCT03437304 / Completed临床1/2期

A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)

This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years) following Immunose™ FLU vaccination at 5 sites in Sweden. A total of 300 subjects will be randomised to 1 of 7 treatment groups. The hypothesis is that Immunose™ FLU is safe and tolerable and will increase the influenza-specific mucosal immune response in older adults.

开始日期2018-02-09

申办/合作机构

Eurocine Vaccines AB

100 项与 Immunose FLU(Eurocine Vaccines AB) 相关的临床结果

登录后查看更多信息

100 项与 Immunose FLU(Eurocine Vaccines AB) 相关的转化医学

登录后查看更多信息

100 项与 Immunose FLU(Eurocine Vaccines AB) 相关的专利（医药）

登录后查看更多信息

100 项与 Immunose FLU(Eurocine Vaccines AB) 相关的药物交易

登录后查看更多信息